US Stock MarketDetailed Quotes
SLRX Salarius Pharmaceuticals
- 1.5200
- -0.0200-1.30%
Close Nov 6 16:00 ET
2.19MMarket Cap-174P/E (TTM)
1.5408High1.4800Low17.91KVolume1.5400Open1.5400Pre Close27.10KTurnover1.28%Turnover RatioLossP/E (Static)1.44MShares7.272052wk High0.92P/B2.14MFloat Cap1.260052wk Low--Dividend TTM1.40MShs Float124099.9504Historical High--Div YieldTTM3.95%Amplitude1.2600Historical Low1.5120Avg Price1Lot Size
About Salarius Pharmaceuticals Company
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Company Profile
SymbolSLRX
Company NameSalarius Pharmaceuticals
Listing DateJan 29, 2015
Issue Price16.00
Founded2014
CEOMr. David J. Arthur
MarketNASDAQ
Employees2
Fiscal Year Ends12-31
Address2450 Holcombe Boulevard,Suite X
CityHouston
ProvinceTexas
CountryUnited States of America
Zip Code77021
Phone1-832-834-6992
Websitehttp://salariuspharma.com
Company Executives
- Name
- Position
- Salary
- David J. Arthur
- Chief Executive Officer
- 544.60K
- Mark J. Rosenblum
- Executive Vice President, Finance and Chief Financial Officer
- 355.76K
- Dr. William K. McVicar, PhD
- Chairman of the Board
- 82.26K
- Jonathan I. Lieber, M.B.A.
- Independent Director
- 53.76K
- Tess Burleson
- Independent Director
- 64.76K
- Dr. Paul Lammers, M. Sc.,M.D.
- Lead Independent Director
- 76.76K
- Dr. Bruce J. McCreedy, PhD
- Independent Director
- 45.26K
- Arnold C. Hanish
- Independent Director
- 67.26K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data